Kendle upgraded to buy by Jefferies

Jefferies & Co., Inc. analyst David Windley upgraded Kendle International Inc. to a buy and a $32 price target. The sell-off of the company is expected to slow organic growth from recent quarters, according to the analyst. Kendle announced the closure of the Charles River phase 2-4 operations acquisition on Aug. 16. Updated guidance is expected soon. Shares of the Cincinnati-based clinical research organization were up $1.21, or 4.69%, at $27.02, on volume of 537,385 shares versus the three-month running average of 286,436 shares. (Nasdaq: KNDL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.